DexCom stock trades below its 52-week high as Truist lifts target

DexCom stock was trading at USD 87.02 on Nasdaq on September 24, 2026 at 12:02 p.m. ET, down 0.80 percent from the prior close of USD 87.73. The move leaves the price 6.02 percent below its 52-week high of USD 92.59.

Truist raises its price target

A September 17, 2026 report published by Yahoo Finance said Truist lifted its DexCom target from USD 93 to USD 102 and maintained a Buy rating.

The USD 9 increase puts the new target 17.21 percent above the September 24 share price. That comparison matters because the stock is trading below its yearly high even after the target revision.

Revenue grows 13.1 percent

DexCom's latest reported quarter delivered USD 1.31 billion in revenue, up 13.1 percent from the same period a year earlier. MarketBeat said the figure exceeded the USD 1.29 billion analyst estimate.

The same report listed earnings per share at USD 0.70 versus a USD 0.61 consensus estimate, a USD 0.09 beat. Revenue growth and the earnings comparison give the valuation debate a concrete operating anchor rather than relying only on analyst targets.

Stock stays below its yearly high

DexCom's market capitalization stood at USD 32,839,765,553 on September 24, 2026. The 52-week range was USD 54.11 to USD 92.59, placing the current quote closer to the upper end than to the yearly low while still 6.02 percent below the high.

The combination of 13.1 percent revenue growth, a USD 102 Truist target and a price below USD 92.59 gives investors three measurable reference points for the stock. The next market question is whether operating growth can narrow the gap between the current quote and the target range.